Text

Nicole Engel-Nitz, PhD 

Text

Nicole Engel-Nitz, PhD

Associate Director

Oncology and Immunology

Text

Dr. Nicole Engel-Nitz joined Optum in 2003 and holds a Doctorate in Health Services Research, Policy and Administration from the University of Minnesota. 

Her presentations at national and international conferences and peer-reviewed publications focus on oncology and rare diseases.

Text

Published work

Reyes C, Engel-Nitz N, DaCosta Byfield S, et al. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. Oncologist. 2019 Feb 22.

Engel-Nitz NM, Liu Z, Blauer-Peterson C, Johnson J. Rare Diseases in the Era of Big Data: Selection Bias in Small Samples. Workshop presented at: ISPOR 20th Annual International Meeting; 2015 May 16-20; Philadelphia, PA.

Engel-Nitz NM, Hao Y, Becker LK, Gerdes R. Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer. J Comp Eff Res. 2015 Aug;4(4):303-14.

Engel-Nitz NM, Yu EB, Becker LK, Small A. Service setting impact on costs for bevacizumab-treated oncology patients. Am J Manag Care. 2014 Nov 1;20(11):e515-22.

Whyte JL, Engel-Nitz NM, Teitelbaum A, Gomez Rey G, Kallich JD. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015 Jul;53(7):e49-57.

Expertise

HEOR, Health Economics Outcomes Research, Health Economics, Oncology, Rare Disease